Figure 1

Kaplan-Meier curve of progression-free survival following treatment with bevacizumab in combination with docetaxel and thalidomide, n = 60 (A) , or bevacizumab in combination with sorafenib, n = 27 (B) , or sorafenib alone or in combination with bevacizumab, or cetuximab in patients with prostate cancer, various solid tumors, colon cancer, or NSCLC n = 113 (C) , or overall survival following treatment with bevacizumab in combination with sorafenib, n = 26 (D) versus development of ≥ Grade 2 toxicity - - or < Grade 2 toxicity ------ as indicated on each respective figure. Respective P = 0.0009, P = 0.052, P = 0.0003, and P = 0.0068 by a two-tailed log-rank test.